Finance Watch: Omega, Perceptive/Xontogeny Raise $648m For Life Science Investments

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.

Finance Watch

With big pharma companies on the hunt for new drug candidates to fill their research and development pipelines, demand for innovative ideas from external partners is only increasing, which is why Omega Funds continues to attract the attention of investors for its life science investment funds. The firm announced on 11 December that it closed its sixth fund – Omega Fund VI LP – with $438m to back new and growing drug developers.

Omega’s announcement followed the news on 10 December that Perceptive Advisors teamed up with the Chris Garabedian-founded accelerator Xontogeny for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.